Vivos Therapeutics, Inc.: total liabilities
Total liabilities for Vivos Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Vivos Therapeutics, Inc. financial histories
What this measure means
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
Exact concept: us-gaap:Liabilities. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 26,702,000 | USD | 2026-04-15 | 10-K · 0001493152-26-016854 |
| At date | 2024-12-31 | 7,330,000 | USD | 2026-04-15 | 10-K · 0001493152-26-016854 |
| At date | 2023-12-31 | 10,319,000 | USD | 2025-03-31 | 10-K · 0001641172-25-001750 |
| At date | 2022-12-31 | 8,919,000 | USD | 2024-07-30 | 10-K/A · 0001493152-24-029491 |
| At date | 2021-12-31 | 8,150,000 | USD | 2023-03-30 | 10-K · 0001493152-23-009765 |
| At date | 2020-12-31 | 8,410,000 | USD | 2022-03-31 | 10-K · 0001493152-22-008452 |
| At date | 2019-12-31 | 9,177,929 | USD | 2021-03-25 | 10-K · 0001493152-21-006806 |
Related financial histories
- Vivos Therapeutics, Inc.: total assets
- Vivos Therapeutics, Inc.: stockholders equity
- Vivos Therapeutics, Inc.: cash and cash equivalents
- Vivos Therapeutics, Inc.: net income or loss
- Vivos Therapeutics, Inc.: operating cash flow
- Vivos Therapeutics, Inc.: capital expenditure payments
- Vivos Therapeutics, Inc.: contract revenue excluding tax
- Vivos Therapeutics, Inc.: financing cash flow
- Vivos Therapeutics, Inc.: investing cash flow
- Vivos Therapeutics, Inc.: retained earnings or deficit
- Vivos Therapeutics, Inc.: basic weighted-average shares
- Vivos Therapeutics, Inc.: diluted weighted-average shares
- Vivos Therapeutics, Inc.: basic earnings per share
- Vivos Therapeutics, Inc.: diluted earnings per share
- Vivos Therapeutics, Inc.: net property, plant and equipment
- Vivos Therapeutics, Inc.: share-based compensation expense
- Vivos Therapeutics, Inc.: operating income or loss
- Vivos Therapeutics, Inc.: current assets
- Vivos Therapeutics, Inc.: interest expense
- Vivos Therapeutics, Inc.: current liabilities
- Vivos Therapeutics, Inc.: current accounts payable
- Vivos Therapeutics, Inc.: goodwill carrying amount
- Vivos Therapeutics, Inc.: net finite-lived intangible assets
- Vivos Therapeutics, Inc.: net current accounts receivable
- Vivos Therapeutics, Inc.: operating expenses
- Vivos Therapeutics, Inc.: gross profit
- Vivos Therapeutics, Inc.: cost of revenue
- Vivos Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Vivos Therapeutics, Inc. / CIK 0001716166
- Captured
- 2026-09-21T17:26:59.972Z
- SEC response SHA-256
efd07425d40bc920d359ff76b1334c560a1babfb4f9db602e6a12742d0495542
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001716166.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))